One of the first questions patients ask when they call us about kratom or 7-OH dependence is whether the medication we use actually works for kratom. The short answer is yes — it works the same way and for the same reason it works for other opioid use disorders. Here’s the clinical picture.
The Pharmacology Line That Makes It Work
Kratom produces opioid-like effects because two of its alkaloids — mitragynine and 7-hydroxymitragynine (7-OH) — activate the mu-opioid receptor in the brain. That’s the same receptor targeted by heroin, fentanyl, morphine, oxycodone, hydrocodone, and the rest of the opioid class. 7-OH is the more potent of the two, and concentrated 7-OH products deliver doses far higher than the plant naturally produces.
Buprenorphine — the active ingredient in Suboxone, Sublocade, and Brixadi — is a partial agonist at that same mu-opioid receptor. Partial agonist means it activates the receptor, but only to a certain ceiling — enough to stop cravings and prevent withdrawal, not enough to produce euphoria or escalating reinforcement. Because kratom works on the same receptor, buprenorphine fills the seat kratom was filling. The cravings quiet. The withdrawal stops. The daily cycle breaks.
This is not off-label or experimental. Buprenorphine’s mechanism makes it mechanistically appropriate for any mu-opioid dependence, including kratom. Our providers treat kratom and 7-OH dependence with the same evidence base and protocol used for prescription-opioid or heroin dependence.
Induction Timing for Kratom Patients
The one clinical wrinkle at the start of treatment is timing. Buprenorphine binds more tightly to the mu receptor than mitragynine or 7-OH does, so taking Suboxone while there’s still meaningful kratom activity in your system can displace it and trigger precipitated withdrawal — a sudden-onset severe withdrawal that is avoidable with correct timing.
For kratom and 7-OH:
- Wait roughly 12 to 24 hours after your last dose before induction, depending on the product. Leaf kratom clears faster than concentrated 7-OH, and long-duration daily 7-OH use can require the longer end of that window.
- Your COWS score is the actual gatekeeper. The Clinical Opiate Withdrawal Scale measures observable withdrawal signs (sweating, pupil size, tremor, GI symptoms, anxiety). Most protocols want a score of at least 8 to 12 before the first buprenorphine dose. If you’re below that at your visit, your provider will either reschedule or use a micro-induction protocol.
- Concentrated 7-OH may require a longer wait than leaf kratom because 7-OH’s receptor binding can be slower to clear. Your provider will adjust based on what you tell them about the product, dose, and use pattern.
This is why we do intake and induction at the clinic rather than sending patients home with a prescription to start on their own. Getting the timing right is the difference between a smooth first dose and a rough one. For more on this specific clinical hazard, see our objection-handling page on precipitated withdrawal.
What the First Dose Feels Like
Assuming the timing is right and your COWS score is in the appropriate range, the first buprenorphine dose produces noticeable relief within 30 to 90 minutes. Patients who came in with early kratom withdrawal — the aches, sweating, anxiety, GI discomfort — typically describe the symptoms subsiding rather than intensifying. Cravings drop. Sleep becomes possible.
Most kratom patients reach a stable daily dose within the first several days. Exact dose varies by individual, but kratom and 7-OH patients often stabilize at lower Suboxone doses than heroin or fentanyl patients — not always, but commonly — because the mu-receptor tolerance built up on kratom is usually less extreme than tolerance built up on full-agonist opioids. Your provider will titrate based on how you respond.
Daily Suboxone vs. Monthly Injection
Once you’re stable on buprenorphine, the medication can be delivered multiple ways:
- Suboxone (film or tablet): daily sublingual dose, placed under the tongue. Most patients start here. The daily dosing gives your provider the flexibility to adjust quickly during the stabilization window.
- Sublocade (monthly injection): once-monthly extended-release buprenorphine injection, administered at the clinic. Many kratom patients who have had dose-stacking or multiple-times-per-day kratom patterns prefer Sublocade precisely because it removes daily medication decisions — the pattern that reinforced their kratom use doesn’t map onto a monthly injection.
- Brixadi (weekly, bi-weekly, or monthly injection): another extended-release buprenorphine option with more flexible intervals than Sublocade. Useful if you want the injection route but a shorter cadence than monthly.
For kratom patients, moving to a long-acting injection after a few weeks on daily Suboxone is a common path. You don’t have to decide on day one — you can start on Suboxone and switch later.
The First Week
Expect the first several days on Suboxone to look like a steady return to baseline, not a dramatic transformation. Cravings quiet. Sleep improves, though it may remain lighter than pre-kratom baseline for a few weeks. Mild side effects — headache, constipation, sometimes nausea — are common early and usually resolve within the first week. Your appetite returns. The mental space that kratom used to occupy is suddenly available for other things.
Common first-week checkpoints:
- Day 1–2: dose adjustment as your provider finds your stable level. Expect a couple of phone or in-person touchpoints.
- Day 3–7: physical symptoms settle; cravings should be substantially quieter. Sleep begins to normalize.
- End of week 1: first follow-up visit. Your provider confirms stability, discusses side-effect management, and starts planning next steps — whether to stay on daily Suboxone or transition to a long-acting injection.
- Week 2 and beyond: mood, energy, and motivation continue to improve as brain chemistry normalizes. The post-acute “flat” feeling common in unsupported kratom withdrawal is usually much less pronounced on MAT.
Why MAT Works When Self-Taper Doesn’t
A lot of kratom patients arrive at our clinic after one or more self-taper attempts that didn’t hold. This isn’t a character failure. The neurobiology explains it: receptors that adapted to daily kratom activation don’t de-adapt on a schedule a person can white-knuckle through. The cravings and low mood that drive relapse are real physical signals, not weakness.
MAT addresses that directly. Instead of removing the signal gradually through a taper (and absorbing the withdrawal hit at the end), it replaces kratom’s effect on receptors with a stable partial-agonist signal — which ends the withdrawal cycle without the painful ramp-down. The patient’s job during this stage is to engage with counseling and rebuild the parts of life that kratom was compressing. The medication makes that bandwidth available.
This is also why, for patients considering a taper, our clinical recommendation usually leans toward MAT first, taper later. See our article on how to taper off kratom for the cases where a slow self-taper is realistic and where it isn’t.
What About People Who Are Using Kratom and Other Opioids?
This is common and doesn’t complicate treatment in the way patients sometimes fear. Buprenorphine addresses both kratom and other opioid use at the same receptor level — the induction covers both. The intake conversation will include the full picture of what you’re using so the timing and dose are right, but one medication plan handles both. Polysubstance use (with alcohol, benzodiazepines, or stimulants) is a separate conversation your provider will have with you at intake.
Getting Started
If you’re ready to stop using kratom or 7-OH and want to talk to someone about medication-assisted treatment, call 423-498-2000 or submit a contact request. Same-week appointments are available at all four of our clinic locations across Tennessee and Georgia. Our intake team will verify your insurance benefits before your first visit.
For a broader picture of how we approach kratom dependence clinically, see our kratom and 7-OH treatment page, or for the withdrawal arc itself, what the typical withdrawal timeline looks like.